Analytical Data
-
基因名
Serum amyloid A
-
简介
Serum amyloid A is a major acute phase reactant, plays a dynamic role in the acute phase response and serves as an essential apolipoprotein in high-density lipoprotein (HDL) complexes. Enhanced expression during the acute phase response reflects its overall involvement in the body's adaptive response to different challenges. Serum amyloid A protein, Cat (P.pastoris, His) is the recombinant cat-derived Serum amyloid A protein, expressed by P. pastoris , with N-His labeled tag.
- Application
-
别名
SAA1; Serum amyloid A protein
-
种属
Cat
-
表达系统
P. pastoris
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P19707
-
表达区间
E1-G90
-
蛋白长度
Partial
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Serum amyloid A (SAA) is an acute-phase protein that plays a critical role in inflammation and immune response. Elevated levels of SAA are associated with various inflammatory conditions, including infections, autoimmune diseases, and chronic inflammatory disorders, and are considered a biomarker for disease activity. The interest in recombinant SAA protein stems from its potential therapeutic applications and its role in understanding the pathophysiology of amyloidosis, a condition characterized by abnormal protein aggregation. Researchers aim to produce recombinant SAA to study its structure-function relationship, investigate its biological activities, and explore its interaction with lipoproteins and immune cells. This research could lead to novel diagnostic tools and therapeutic strategies for diseases linked with SAA dysregulation. Moreover, recombinant SAA provides an opportunity to dissect its role in amyloid formation and to develop interventions that may inhibit or modify this process. As the understanding of SAA’s mechanisms evolves, it may pave the way for innovative treatments that target inflammation and its sequelae, enhancing patient outcomes in various diseases driven by chronic inflammatory processes.
